Monographie - Daptomycin

Dernière mise à jour :
18/04/2024

Daptomycin

Structure chimique

Noms commerciaux

Les noms commerciaux sont donnés à titre indicatif et la composition en excipients peut être différente selon les pays et selon les laboratoires

Cubicin	Allemagne, Argentine, Autriche, Canada, Chili, Colombie, Danemark, Espagne, Etats Unis d’Amérique, Finlande, France, Grande Bretagne, Grèce, Hongrie, Inde, Irlande, Islande, Italie, Japon, Luxembourg, Malaisie, Mexique, Norvège, Nouvelle Zélande, Pays bas, Pologne, Portugal, Roumanie, Suède, Suisse, Turquie, Vénézuela
Daptomicina	Espagne
Daptomicine	Grande Bretagne

Bibliographie : Daptomycin

	Type	Source
1937	Revue	Lai JJ, Brodeur SK. Physical and chemical stability of daptomycin with nine medications. Ann Pharmacotherapy 2004 ; 38: 1612-1616.
2247	Revue	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	Revue	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2271	Laboratoire	Daptomycine (Cubicin®) Résumé des caractéristiques du produits Novartis 2006
3122	Revue	Dotson B, Lynn S, Savakis K, Churchwell MD. Physical compatibility of 4% sodium citrate with selected antimicrobial agents. Am J Health-Syst Pharm 2010 ; 67: 1195-1198.
3218	Revue	Peyro Saint Paul L, Albessard F, Gaillard C, Debruyn D, Ryckelynck J Ph, Antoine Coquerel, Lobbedez T Daptomycin Compatibility in Peritoneal Dialysis Solutions Perit Dial Int 2011 ; 31: 492?495.
3439	Revue	Parra M.A, Campanero M.A, S?daba B, Irigoyen A, Garc?a-L?pez L,Fernandez-Reyes M.J, Ramon Azanza J. Effect of Glucose Concentration on the Stability of Daptomycin in Peritoneal Solutions. Perit Dial Int 2013 ; 33:458-461
3665	Revue	Ortega R, Salmer?n-Garc?a A, Cabeza J, Capit?n-Vallvey L.F, Navas N. Stability of daptomycin 5 mg/mL and heparin sodium 100 units/mL combined in lactated Ringer’s injection and stored in polypropylene syringes at 4 and -20°C. Am J Health-Syst Pharm 2014 ; 71:956-959
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3976	Revue	Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B. Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration. Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218
4055	Revue	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4074	Revue	Ferrandez J, Sanchez R, Diaz D, Diaz M, Estevan M, Garcia T. Stability of daptomycin reconstituted vials and infusion solutions. EJHP 2018 ; 25: 107-110.
4145	Revue	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4254	Revue	D'Huart E, Vigneron J, Demoré B. Physical Compatibility of Intravenous Drugs Commonly Used in Intensive Care Units: An Observational Study and Physical Compatibility Laboratory Tests on Anti-Infective Drugs Pharmaceutical Technology in Hospital Pharmacy 2019 ;4,1:29-40
4380	Laboratoire	Posaconazole (Noxafil®) - Summary of Product Characteristics Merck Sharp & Dohme Limited 2019
4528	Revue	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61

Mentions Légales